Webinar
Bioprocessing Revisited: Applying the Lessons from mAbs Production to Advanced Therapeutics Manufacturing
December 04, 2024 11:00 AM US/Eastern
Biotherapeutic manufacturers must move beyond traditional batch and fed-batch processing and look to adopt continuous approaches to increase dose production, reduce costs, and maintain consistent quality. Join a panel of experts from Repligen as we discuss how the lessons learned from monoclonal antibodies (mAbs) production can be applied to advanced therapeutic medicinal products (ATMPs) including gene therapies, cell therapies, nucleic acid-based therapies, oncolytics, vaccines, and exosomes. We will explore the high-impact innovations driving process efficiency in mAbs and vector-based therapeutics production today, from upstream process intensification and downstream chromatography and advanced TFF systems with integrated real-time process analytics, and how these solutions can streamline processes, ensuring higher productivity, scalability, affordability, and accessibility for the therapies of tomorrow.
Webinar Learning Objectives
Understand the innovative technologies and strategies that led to boosted mAbs productivity, reduced COGS, and improved quality.
Examine how scalable N perfusion and intensified fed-batch using N-1 perfusion in mAbs and viral vector production can lead to 3X improvements in space-time yield
Learn how to overcome the unique challenges of advanced therapeutics, ensuring higher productivity, scalability, and cost-effectiveness in ATMP manufacturing.
Rachel Legmann
Rachel Leggman has over 25 years of experience in scalable biologics and in gene therapy manufacturing of therapeutic products. She completed her Ph.D. in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology in Israel. Rachel joined Repligen in 2021 as a subject matter expert, leading the global gene therapy organization to help customers achieve their technical and operational objectives in manufacturing vector-based therapeutics and vaccines, with a focus on gene therapy processes including upstream, downstream, analytics, and scalability. Prior to joining Repligen, Rachel held several scientific and leadership roles: at the Microbiology & Molecular Genetics Department at Harvard Medical School; at SBH Sciences, a CRO; at Seahorse Biosciences, part of Agilent; at Goodwin Biotechnology, a CDMO; and at Pall Corp/Danaher.
René Gantier
René Gantier has over 20 years of experience developing production and purification processes for biotherapies. In his current role, he leads the development of advanced bioprocess applications and technologies with a focus on next-generation cell and gene therapy manufacturing processes. Before joining Repligen, he led the Biotech Process R&D team at Pall Life Sciences, where he developed end-to-end upstream-downstream continuous bioprocessing solutions for mAbs and cell/gene therapies. René holds an MSc in Cell Biology from the University of Nantes (France) and a PhD in Biochemistry from the University of Rouen (France).
Harlan Knapp
Harlan Knapp currently leads the global upstream applications team for process intensification utilizing membrane-based technology. He has spent the past 20 years in the biopharmaceutical industry in a variety of roles, including R&D, Applications, Manufacturing, Product Development, Management, Sales, and C-Suite Business Development. He received his Master of Science in Biology from Eastern Washington University. He is based in Seattle, WA, where he enjoys roasting and preparing Espresso coffee and spending time outdoors with his family.
Robin Butler
Robin Butler has 35 years of experience in the bioprocess industry, specializing in upstream bioprocessing. Most recently, she spent eight years at Cytiva, where she focused on HyClone™ products, custom services, and lab consumables. Prior to Cytiva, Robin held key marketing, sales, and product management roles at Pall Corporation and Harvard Apparatus. Early in her career, she gained valuable research experience at Yale University, Genzyme, and GTC Biotherapeutics.